Research ArticleOriginal Article
Open Access

Association of the 6-minute walking test ratio and difference with pulmonary function in patients with interstitial lung disease

Ru Yang, Yuguang Wang, Li Hao, Guomin Zhao and Xitong Liu
Saudi Medical Journal October 2023, 44 (10) 1000-1005; DOI: https://doi.org/10.15537/smj.2023.44.10.20220940

References

  1. 1.↵
    1. McCarthy C,
    2. Keane MP.
    Contemporary concise review 2021: Interstitial lung disease. Respirology 2022; 27: 539–548.
    OpenUrl
  2. 2.↵
    1. Antoine MH,
    2. Mlika M.
    Interstitial lung disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
  3. 3.↵
    1. Bradley B,
    2. Branley HM,
    3. Egan JJ,
    4. Greaves MS,
    5. Hansell DM,
    6. Harrison NK, et al.
    Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63: v1–58.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Dempsey OJ,
    2. Kerr KM,
    3. Remmen H,
    4. Denison AR.
    How to investigate a patient with suspected interstitial lung disease. BMJ 2010; 340: c2843.
    OpenUrlFREE Full Text
  5. 5.↵
    1. Wijsenbeek M,
    2. Cottin V.
    Spectrum of fibrotic lung diseases. N Engl J Med 2020; 383: 958–968.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Matos Casano HA,
    2. Anjum F.
    Six-minute walk test. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
  7. 7.↵
    1. Wang J,
    2. Zang Y,
    3. Wu Q,
    4. She Y,
    5. Xu H,
    6. Zhang J, et al.
    Predicting adverse events during six-minute walk test using continuous physiological signals. Front Physiol 2022; 13: 887954.
    OpenUrl
  8. 8.↵
    1. Giannitsi S,
    2. Bougiakli M,
    3. Bechlioulis A,
    4. Kotsia A,
    5. Michalis LK,
    6. Naka KK.
    6-Minute walking test: A useful tool in the management of heart failure patients. Ther Adv Cardiovasc Dis 2019; 13: 1753944719870084.
    OpenUrlPubMed
  9. 9.↵
    1. Brown AW,
    2. Nathan SD.
    The value and application of the 6-minute-walk test in idiopathic pulmonary fibrosis. Ann Am Thorac Soc 2018; 15: 3–10.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Agrawal MB,
    2. Awad NT.
    Correlation between six minute walk test and spirometry in chronic pulmonary disease. J Clin Diagn Res 2015; 9: OC01–OC04.
    OpenUrl
  11. 11.↵
    1. Lancaster LH.
    Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med 2018; 13: 45.
    OpenUrl
  12. 12.↵
    1. Akbay NO,
    2. Bingol Z,
    3. Kiyan E,
    4. Karaayvaz EB,
    5. Bilge AK,
    6. Issever H, et al.
    Fractional exhaled nitric oxide measurement in pulmonary hypertension: A follow-up study. Clin Appl Thromb Hemost 2018; 24: 483–488.
    OpenUrlPubMed
  13. 13.↵
    1. Malekmohammad M,
    2. Folkerts G,
    3. Kashani BS,
    4. Naghan PA,
    5. Dastenae ZH,
    6. Khoundabi B, et al.
    Exhaled nitric oxide is not a biomarker for idiopathic pulmonary arterial hypertension or for treatment efficacy. BMC Pulm Med 2019; 19: 188.
    OpenUrl
  14. 14.↵
    1. Duncan MJ,
    2. Mota J,
    3. Carvalho J,
    4. Nevill AM.
    An evaluation of prediction equations for the 6 minute walk test in healthy european adults aged 50-85 years. PLoS One 2015; 10: e0139629.
    OpenUrl
  15. 15.↵
    1. Holland AE,
    2. Dowman L,
    3. Fiore J, Jr.,
    4. Brazzale D,
    5. Hill CJ,
    6. McDonald CF.
    Cardiorespiratory responses to 6-minute walk test in interstitial lung disease: not always a submaximal test. BMC Pulm Med 2014; 14: 136.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Porteous MK,
    2. Rivera-Lebron BN,
    3. Kreider M,
    4. Lee J,
    5. Kawut SM.
    Determinants of 6-minute walk distance in patients with idiopathic pulmonary fibrosis undergoing lung transplant evaluation. Pulm Circ 2016; 6: 30–36.
    OpenUrlPubMed
  17. 17.↵
    1. Holland AE.
    Functional capacity in idiopathic pulmonary fibrosis: Looking beyond the lungs. Respirology 2015; 20: 857–858.
    OpenUrl
  18. 18.↵
    1. Modi P,
    2. Cascella M.
    Diffusing capacity of the lungs for carbon monoxide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
  19. 19.↵
    1. Rizzi M,
    2. Sarzi-Puttini P,
    3. Airoldi A,
    4. Antivalle M,
    5. Battellino M,
    6. Atzeni F.
    Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease. Clin Exp Rheumatol 2015; 33: S142–147.
    OpenUrl
  20. 20.↵
    1. Mancuzo EV,
    2. Soares MR,
    3. Pereira CAC.
    Six-minute walk distance and survival time in patients with idiopathic pulmonary fibrosis in Brazil. J Bras Pneumol 2018; 44: 267–272.
    OpenUrl
  21. 21.
    1. Khor YH,
    2. Farooqi M,
    3. Hambly N,
    4. Johannson KA,
    5. Marcoux V,
    6. Fisher JH, et al.
    Trajectories and Prognostic Significance of 6-Minute Walk test parameters in fibrotic interstitial lung disease: A multicenter study. Chest 2023; 163: 345–357.
    OpenUrl
  22. 22.↵
    1. Nishiyama O,
    2. Yamazaki R,
    3. Sano H,
    4. Iwanaga T,
    5. Higashimoto Y,
    6. Kume H, et al.
    Pulmonary hemodynamics and 6-minute walk test outcomes in patients with interstitial lung disease. Can Respir J 2016; 2016: 3837182.
    OpenUrl
  23. 23.↵
    1. du Bois RM,
    2. Weycker D,
    3. Albera C,
    4. Bradford WZ,
    5. Costabel U,
    6. Kartashov A, et al.
    Six-minute-walk test in idiopathic pulmonary fibrosis: Test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183: 1231–1237.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.
    1. Kozu R,
    2. Jenkins S,
    3. Senjyu H.
    Evaluation of activity limitation in patients with idiopathic pulmonary fibrosis grouped according to Medical Research Council dyspnea grade. Arch Phys Med Rehabil 2014; 95: 950–955.
    OpenUrlPubMed
  25. 25.
    1. du Bois RM,
    2. Albera C,
    3. Bradford WZ,
    4. Costabel U,
    5. Leff JA,
    6. Noble PW, et al.
    6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 2014; 43: 1421–1429.
    OpenUrlAbstract/FREE Full Text
  26. 26.
    1. Leuchte HH,
    2. Mernitz P,
    3. Baezner C,
    4. Baumgartner RA,
    5. von Wulffen W,
    6. Neurohr C, et al.
    Self-report daily life activity as a prognostic marker of idiopathic pulmonary fibrosis. Respiration 2015; 90: 460–467.
    OpenUrl
  27. 27.↵
    1. Ley B,
    2. Bradford WZ,
    3. Vittinghoff E,
    4. Weycker D,
    5. du Bois RM,
    6. Collard HR.
    Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016; 194: 711–718.
    OpenUrl
  28. 28.↵
    1. Dweik RA,
    2. Boggs PB,
    3. Erzurum SC,
    4. Irvin CG,
    5. Leigh MW,
    6. Lundberg JO, et al.
    An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184: 602–615.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Miskoff JA,
    2. Dewan A,
    3. Chaudhri M.
    Fractional exhaled nitric oxide testing: Diagnostic utility in asthma, chronic obstructive pulmonary disease, or asthma-chronic obstructive pulmonary disease overlap syndrome. Cureus 2019; 11: e4864.
    OpenUrl
  30. 30.↵
    1. Lin G,
    2. Zhang Z,
    3. Li X.
    Evaluation of fractional exhaled nitric oxide in interstitial lung disease. Chest 2020; 158: A2628.
    OpenUrl
  31. 31.↵
    1. Zheng Y,
    2. Lou Y,
    3. Zhu F,
    4. Wang X,
    5. Wu W,
    6. Wu X.
    Utility of fractional exhaled nitric oxide in interstitial lung disease. J Breath Res 2021; 15.
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords